← back to search

María Virginia Villegas

Universidad El Bosque · CO
Area of research
Molecular Medicine · Applied Microbiology and Biotechnology
Research interest
Research interests include Antibiotic Resistance in Bacteria, Antibiotic Use and Resistance, Antibiotics Pharmacokinetics and Efficacy, and Bacterial Identification and Susceptibility Testing.
h-index
49
citations
17,113
works
206
NIH funding
primary concept
Medicine
email

Recent publications

Resistance to novel β-lactam/β-lactamase inhibitors among carbapenem-resistant <i>Pseudomonas aeruginosa</i> and clinical implications in the prospective observational <i>Pseudomonas</i> study.
2026cited by 0position: contributordoi
Dissemination of Extended-Spectrum β-Lactamase-Producing Enterobacterales in Organic Fertilizers: A One Health Perspective from Southwestern Colombia
Environments 2026cited by 0position: contributordoi
Antimicrobial stewardship interventions reduce the time to the first antibiotic administration in septic patients in ICUs: regional multicenter study in 7 Latin American high-complexity hospitals.
2025cited by 0position: contributordoi
Emergence and dissemination of <i>bla</i><sub>KPC-31</sub> and <i>bla</i><sub>PAC-2</sub> among different species of Enterobacterales in Colombia: a new challenge for the microbiological laboratories.
2025cited by 0position: contributordoi
Current and future options for the treatment of serious infections due to carbapenem-resistant <i>Pseudomonas aeruginosa</i>.
2025cited by 0position: contributordoi
In vitro activity of cefiderocol against a global collection of carbapenem-resistant Pseudomonas aeruginosa with a high level of carbapenemase diversity.
2024cited by 16position: contributordoi
First report of KPC variants conferring ceftazidime-avibactam resistance in Colombia: introducing KPC-197.
2024cited by 9position: contributordoi
Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study
The Lancet Microbe 2023cited by 281position: middledoi
Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study.
2023cited by 209position: contributordoi
Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant <i>Acinetobacter baumannii</i> Among Patients From Different Global Regions
Clinical Infectious Diseases 2023cited by 88position: middledoi
International Epidemiology of Carbapenemase-Producing Escherichia coli.
2023cited by 29position: contributordoi
Rapid Diagnostic Test Value and Implementation in Antimicrobial Stewardship Across Low-to-Middle and High-Income Countries: A Mixed-Methods Review
Infectious Diseases and Therapy 2023cited by 22position: middledoi
Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of <i>Enterobacterales</i> and Pseudomonas aeruginosa in Latin American Hospitals.
2023cited by 20position: contributordoi
Rapid Diagnostic Test Value and Implementation in Antimicrobial Stewardship Across Low-to-Middle and High-Income Countries: A Mixed-Methods Review.
2023cited by 19position: contributordoi
Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant <i>Pseudomonas aeruginosa</i>
Journal of Antimicrobial Chemotherapy 2023cited by 19position: contributordoi
Antimicrobial stewardship programs in seven Latin American countries: facing the challenges.
2023cited by 16position: contributordoi
Antimicrobial Stewardship Programs in Latin America and the Caribbean: A Story of Perseverance, Challenges, and Goals.
2023cited by 12position: contributordoi
Identification of <i>mcr-1</i> Genes and Characterization of Resistance Mechanisms to Colistin in <i>Escherichia coli</i> Isolates from Colombian Hospitals.
2023cited by 6position: contributordoi
Update of antimicrobial resistance in level III and IV health institutions in Colombia between January 2018 and December 2021
2023cited by 5position: contributordoi
Gaps and barriers in the implementation and functioning of antimicrobial stewardship programmes: results from an educational and behavioural mixed-methods needs assessment in France, the United States, Mexico and India-authors' response.
2023cited by 1position: contributordoi
Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study.
2022cited by 261position: contributordoi
Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections
International Journal of Antimicrobial Agents 2022cited by 116position: contributordoi
Early appropriate diagnostics and treatment of MDR Gram-negative infections.
2022cited by 37position: contributordoi
Impact of antimicrobial stewardship programs on antibiotic consumption and antimicrobial resistance in four Colombian healthcare institutions.
2022cited by 20position: contributordoi
Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa.
2022cited by 11position: contributordoi
Global resilience and new strategies needed for antimicrobial stewardship during the COVID-19 pandemic and beyond.
2022cited by 11position: contributordoi
Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of <i>Pseudomonas aeruginosa</i> from five Latin American countries.
2022cited by 11position: contributordoi
Multicenter, Prospective Validation of a Phenotypic Algorithm to Guide Carbapenemase Testing in Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> Using the ERACE-PA Global Surveillance Program.
2022cited by 10position: contributordoi
Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of <i>Pseudomonas aeruginosa</i> and <i>Enterobacterales</i> from Five Latin American Countries.
2022cited by 9position: contributordoi
Gaps and barriers in the implementation and functioning of antimicrobial stewardship programmes: results from an educational and behavioural mixed methods needs assessment in France, the United States, Mexico and India.
2022cited by 8position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 14 papers (2019–2026)Elsa De la Cadena · Universidad El Bosque8 papers (2021–2026)José M. Munita · Universidad del Desarrollo7 papers (2019–2023)Adrian Brink · Wellcome Centre for Infectious Diseases Research in Africa7 papers (2016–2022)Juan Carlos García-Betancur · Universidade de São Paulo5 papers (2022–2025)Maria F. Mojica · Louis Stokes Cleveland VA Medical Center5 papers (2020–2024)Marc Mendelson · Groote Schuur Hospital5 papers (2016–2019) · 4 papers (2022–2026)Yohei Doi · University of Pittsburgh4 papers (2022–2023)Rafael Cantón · Madrid Institute for Advanced Studies4 papers (2021–2021)Marco Falcone · University of Turin4 papers (2021–2022)Jinnethe Reyes · Universidad El Bosque4 papers (2021–2026)Robin Patel · Mayo Clinic4 papers (2022–2026)David van Duin · University of North Carolina at Chapel Hill4 papers (2022–2026)Harald Seifert · Heinrich Heine University Düsseldorf3 papers (2021–2021)David P. Nicolau · Brown University3 papers (2021–2021)Spyros Pournaras · National and Kapodistrian University of Athens3 papers (2021–2021)Lorena Díaz · Universidad del Desarrollo3 papers (2020–2022)Tobias Manuel Appel · European Society of Clinical Microbiology and Infectious Diseases3 papers (2020–2022)Carolyn Tarrant · University of Leicester3 papers (2019–2019)